Darmiyan Receives the US FDA’s Approval for BrainSee to Detect Alzheimer’s Dementia
Shots:
- The company received the US FDA’s approval for BrainSee, an automated software platform that generates an objective score predicting the likelihood of a patient progressing from Amnestic Mild Cognitive Impairment (aMCI) to Alzheimer’s Dementia within a span of 5yrs.
- The software predicts the disease progression by combining standard clinical brain MRI with cognitive assessments incl. routine part & non-invasive workups of patients concerned with memory loss
- Early screening through image processing & medical AI allows timely & personalized treatments for aMCI patients at high risk of progression to Alzheimer's dementia. Additionally, in 2021, Darmiyan received the BTD from the US FDA for BrainSee
Ref: PR Newswire | Image: Darmiyan
Related News:- Eisai and Biogen’s Leqembi (Lecanemab) Receives the NMPA’s Approval for the Treatment of Alzheimer’s Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.
![Life Molecular Imaging’s [18F] PI-2620 Gains the US FDA’s Fast Track Designation for PET Imaging in Various Neurodegenerative Disorders](https://pharmashots.com/public/images/20240829173251_original_43.webp)
